当前位置： SCI文献检索 > JOURNAL OF GLAUCOMA期刊下所有文献 > Glycerin-preserved Human-donor Corneoscleral Patch Grafts for Glaucoma Drainage Devices.

Glycerin-preserved Human-donor Corneoscleral Patch Grafts for Glaucoma Drainage Devices.

Abstract：

PRECIS:Glycerin-preserved, human-donor, corneoscleral patch grafts are effective and safe for glaucoma drainage device (GDD) implantation, and they are comparable to previously reported materials. It can be preserved with the sterile technique for up to 12 months. PURPOSE:To evaluate the efficacy and safety of glycerin-preserved human donor corneoscleral tissue as the patch graft for GDD implantation. PATIENTS AND METHODS:This was a retrospective noncomparative study from the medical records of 102 eyes from 102 glaucoma patients who underwent GDD implantation by or under supervision of a single surgeon (N.K.) at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between January 2006 and December 2016. The glycerin-preserved human-donor corneoscleral tissue was used as the patch graft to cover the tube portion of GDD over the sclera. The primary outcome measure was the occurrence of patch graft-related complications. RESULTS:There were 64 males and 38 females with the mean age of 52.8±18.5 years. The underlying diseases included failed filtration surgery with primary open-angle glaucoma 32 eyes and primary angle-closure glaucoma 15 eyes, congenital glaucoma 3 eyes and secondary glaucoma 52 eyes. The mean of ocular surgeries before GDD implantation was 2.3±1.1. Patch graft-related complications included tube exposure in 4 eyes (3.9%) and wound leakage in 4 eyes (3.9%). Eyes with tube exposure underwent regrafting 3 eyes and tube reposition 1 eye. Eyes with wound leaking resolved spontaneously 2 eyes and underwent conjunctival resuturing 2 eyes. The 5-year survival rate of the corneoscleral graft was 95.7%. There was no recurrence of graft-related complications after surgical procedure to correct the complications. Postoperatively, the mean of intraocular pressure and antiglaucoma medications decreased significantly from 27.4±9.8 mm Hg and 3.8±0.93 to 13.8±6.4 mm Hg (P<0.001) and 1.6±1.5 (P<0.001) at the last visit, respectively. The mean follow-up time was 59.9 months (range, 1 to 144.7 mo). CONCLUSION:The glycerin-preserved human-donor corneoscleral tissue using as the patch graft was a safe alternative for GDD tube coverage. The patch graft-related complications was comparable to other materials.

journal_name

J Glaucoma

journal_title

Journal of glaucoma

authors

Kitnarong N,Srikulsasitorn B,Aurboonsong T

doi

10.1097/IJG.0000000000001610

subject

Has Abstract

pub_date

2020-11-01 00:00:00

pages

1065-1069

issue

eissn

1057-0829

issn

1536-481X

journal_volume

pub_type

杂志文章

在线工具

Glycerin-preserved Human-donor Corneoscleral Patch Grafts for Glaucoma Drainage Devices.